Pfizer, Inc. · NYSE:PFE
Pfizer — Cowen and Company 36th Annual Health Care Conference 2016
13 slides from Pfizer's conference presentation, Mar 8, 2016
Slide 1: Accelerating Impactful Medicines to Market
Accelerating Impactful Medicines to Market Cowen and Company 36th Annual Health Care Conference Mikael Dolsten, M.D., Ph.D. President Pfizer Worldwide R&D March 8, 2016
Slide 2: Forward-looking Statements
Forward-looking Statements • This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts and expected regulatory submissions and approvals that are s
Slide 3: Strong Track Record of Approvals
Strong Track Record of Approvals Over the last 5 years >25 Phase 3 starts & >15 key approvals (10 NME’s) For presentation; not for distribution 3
Slide 4: Robust Pipeline Positioned to Sustain Productivity
Robust Pipeline Positioned to Sustain Productivity ~50% biologics, biosimilars and vaccines 214 Discovery Discovery Phase 1 Phase 2 Phase 3 Registration 90 Projects Projects 34 18 30 8 Total (As of February 2, 2016) Programs with Accelerated Regulatory Pathways Breakthrough Therapy 3 6 Fast Track De
Slide 5: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products Potential for more than 20 approvals, including up to 10 NMEs ONCOLOGY RARE DISEASE Ibrance: Breast Cancer & Beyond rivipansel, PDE9 SCD IO: PD-L1, 4-1BB, OX40, CART, Combo FIX Gene Therapy, TFPI Hemophilia Targeted: inotuzumab, lorlatinib
Slide 6: Potential 2016 News Flow
Potential 2016 News Flow LATE STAGE Xeljanz ertugliflozin PsA Ph 3 Data Ph 3 Data bococizumab LDL Xalkori Ph 3 Data ROS1 NSCLC Approval 1H 2016 2H 2016 EARLY STAGE p-cadherin avelumab Bi-Fx FIH Ovarian,SCCHN POC Dopamine Mod. JAK1 PD Ph 2 Start AD Ph 2 Start For presentation; not for distribution 6
Slide 7: Potential 2016 News Flow
Potential 2016 News Flow LATE STAGE Xeljanz ertugliflozin avelumab inotuzumab PsA Ph 3 Data Ph 3 Data MCC Submission ALL Approval (US) bococizumab LDL Xalkori Xeljanz Ibrance Ph 3 Data ROS1 NSCLC Approval UC Ph 3 Data BC Approval (EU) 1H 2016 2H 2016 CART, IDO1 EARLY STAGE p-cadherin avelumab IO FIH
Slide 8: Ibrance: Cell Cycle Inhibition in Breast Cancer
Ibrance: Cell Cycle Inhibition in Breast Cancer Beyond HR+ / HER2 BC PALLAS PENELOPE-B PEARL Indication Ladder HER2, Triple ER+ eBC Combo etc., PALOMA-2 ER+ eBC (Stage II / III) PALOMA-3 Recurrent (High Risk) IBRANCE PALOMA-1 ER+, HER2- IBRANCE + AI mono/combo mBC or Anti-estrogen IBRANCE + AI Recur
Slide 9: Ibrance: Beyond Breast Cancer
Ibrance: Beyond Breast Cancer NCT02154490 NCT02501902 NCT02499120 Lung MAP Indication Ladder Pancreatic NCT02159755 SCCHN IBRANCE vs IBRANCE + docetaxel NCT02101034 paclitaxel Mantle Cell IBRANCE + Jun 2022 Lymphoma cetuximab Dec 2017 Jun 2017 SCCHN IBRANCE + ibrutinib IBRANCE + Feb 2017 cetuximab A
Slide 10: Pfizer Quickly Becoming a Player in Immuno-Oncology
Pfizer Quickly Becoming a Player in Immuno-Oncology avelumab (PD-L1) is the anchor surrounded by diverse modalities ANTIBODIES 4-1BB, OX-40 avelumab 28 avelumab studies initiated (7 with registration intent) Potential for 1st approval in 2017 SMALL MOLECULES BI-SPECIFICS Potential for 1 approval/yr
Slide 11: Immuno-Oncology: Targeting the Immune Cancer Genome
Immuno-Oncology: Targeting the Immune Cancer Genome avelumab (PD-L1) mUC* 4-1BB + rituximab PD-L1+ (>5%) show increased ORR Durable CR in R-refractory FL & MCL Patients with mUC (n=32) 200 Best Change from Baseline (%) 100 FL PD-L1+ MCL PD-L1- 150 MZL 80 DLBCL 100 Nodular LPHL 60 PFS (%) 50 40 Mixed
Slide 12: Gene Therapy: Targeting Inherited Genome Variability
Gene Therapy: Targeting Inherited Genome Variability Bold Entry into Gene Therapy Gene Therapy Factor IX • Factor IX AAV vector-mediated gene Human FIX Antigen Levels in Cynos transfer approach in hemophilia B Plasma hFIX (ng ml) % of normal hF IX* • Proprietary nextgen AAV vector – Novel bioenginee
Slide 13: Questions
Questions For presentation; not for distribution 13
Pfizer — Cowen and Company 36th Annual Health Care Conference 2016 on 6ix